Morfina 1% Braun (Morphine Hydrochloride Trihydrate)

Morphine works by binding to μ‑opioid receptors in the central nervous system. This activation inhibits the release of excitatory neurotransmitters, reduces neuronal firing, and diminishes the perception of pain. The result is effective analgesia and a degree of sedation, which together help control intense pain signals.

The dose of Morfina 1% Braun is individualized and set by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, weight, organ function, and route of administration. No fixed dosing regimen is provided in product literature; the prescriber calculates the appropriate amount for each case.

Safety of morphine during pregnancy and lactation is not well established. The product is classified as having an unknown pregnancy category, and opioids can cross the placenta and enter breast milk. Use only if the potential benefit justifies the potential risk, and always under close medical supervision.

To order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details—including any cold‑chain requirements—and the necessary import documentation for hospitals, pharmacies, or procurement agencies.

Both morphine and fentanyl are potent opioids, but they differ in potency, onset, and duration. Morphine has a slower onset and longer duration, making it suitable for continuous epidural or intrathecal infusions. Fentanyl is more lipophilic, providing a faster onset and shorter duration, often used for brief procedural analgesia. Choice depends on clinical context and physician judgment.

Morfina 1% Braun should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at ambient temperature, as temperature excursions can affect product stability.

The solution is administered by a qualified healthcare professional via epidural, intramuscular, or intrathecal injection. The specific route, volume, and rate are determined by the prescriber based on the clinical indication, patient condition, and desired analgesic effect. Proper aseptic technique and monitoring are essential during administration.

The most serious risks include respiratory depression, which can be life‑threatening, severe hypotension, and anaphylactic reactions. These events require immediate medical intervention. Continuous monitoring of respiratory function, blood pressure, and signs of allergic response is essential, especially during initiation or dose escalation.

Patients with known hypersensitivity to morphine or any component of the formulation should avoid the product. It is also contraindicated in individuals with severe respiratory insufficiency, acute or severe bronchial asthma, and those taking monoamine oxidase inhibitors within 14 days. Caution is advised in patients with compromised renal or hepatic function.